Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT01740427
Registration number
NCT01740427
Ethics application status
Date submitted
26/11/2012
Date registered
4/12/2012
Date last updated
30/11/2023
Titles & IDs
Public title
A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)
Query!
Scientific title
A RANDOMIZED, MULTICENTER, DOUBLE-BLIND PHASE 3 STUDY OF PD-0332991 (ORAL CDK 4/6 INHIBITOR) PLUS LETROZOLE VERSUS PLACEBO PLUS LETROZOLE FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH ER (+), HER2 (-) BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE
Query!
Secondary ID [1]
0
0
2012-004601-27
Query!
Secondary ID [2]
0
0
A5481008
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Breast Neoplasms
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Breast
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - PD-0332991
Treatment: Drugs - Letrozole
Treatment: Drugs - Placebo
Treatment: Drugs - Letrozole
Experimental: PD-0332991 + Letrozole - PD-0332991, 125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment in combination with Letrozole, 2.5mg, orally once daily (continuously).
Active Comparator: Placebo + Letrozole - Placebo, 125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment in combination with Letrozole, 2.5mg, orally once daily (continuously).
Treatment: Drugs: PD-0332991
PD-0332991, 125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment
Treatment: Drugs: Letrozole
Letrozole, 2.5mg, orally once daily (continuously)
Treatment: Drugs: Placebo
Placebo, 125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment
Treatment: Drugs: Letrozole
Letrozole, 2.5mg, orally once daily (continuously)
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Progression-Free Survival (PFS) as Assessed by the Investigator.
Query!
Assessment method [1]
0
0
PFS is defined as the time from the date of randomization to the date of the first documentation of objective tumor progression as per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) or death due to any cause in the absence of documented PD, whichever occurs first. If tumor progression data include more than 1 date, the first date will be used. PFS (in months) will be calculated as (first event date - randomization date +1)/30.4. Progression is defined using RECIST v1.1, as a 20% increase in the sum of diameters of target measurable lesions above the smallest sum observed (over baseline if no decrease in the sum is observed during therapy), with a minimum absolute increase of 5 mm, or unequivocal progression of pre-existing non-target lesions, or the appearance of new lesions.
Query!
Timepoint [1]
0
0
From randomization date to date of first documentation of progression OR death (up to approximately 2.5 years)
Query!
Secondary outcome [1]
0
0
Objective Response as Assessed by the Investigator
Query!
Assessment method [1]
0
0
Objective Response (OR) defined as the overall complete response (CR) or partial response (PR) according to the RECIST v1.1. Objective Response Rate (ORR) is defined as proportion of patients with CR or PR relative to all randomized patients with measurable disease at baseline. Patients who do not have on-study radiographic tumor re-evaluation, who received anti-tumor treatment, or who died, progressed/ dropped out for any reason prior to reaching a CR or PR were counted as non-responders in the assessment of ORR. Per RECIST v1.1, CR: Complete disappearance of target lesions with exception of nodal disease. All target nodes must decrease to normal size (short axis <10mm). PR: =30% decrease under baseline of the sum of diameters of all target measurable lesions. The short diameter is used in the sum for target nodes, while the longest diameter is used in the sum for all other target lesions. Stable Disease: neither sufficient shrinkage nor increase to qualify for disease progression.
Query!
Timepoint [1]
0
0
From randomization until end of treatment (up to approximately 2.5 years)
Query!
Secondary outcome [2]
0
0
Objective Response: Patients With Measurable Disease at Baseline as Assessed by the Investigator
Query!
Assessment method [2]
0
0
The OR is defined as the overall CR or PR according to the RECIST v1.1. ORR is defined as proportion of patients with CR or PR relative to all randomized patients with measurable disease at baseline. Patients who do not have on-study radiographic tumor re-evaluation, who received anti-tumor treatment, or who died, progressed/ dropped out for any reason prior to reaching a CR or PR were counted as non-responders in the assessment of ORR. Per RECIST v1.1, CR: Complete disappearance of target lesions with exception of nodal disease. All target nodes must decrease to normal size (short axis <10mm). PR: =30% decrease under baseline of the sum of diameters of all target measurable lesions. The short diameter is used in the sum for target nodes, while the longest diameter is used in the sum for all other target lesions. Stable Disease: neither sufficient shrinkage nor increase to qualify for disease progression.
Query!
Timepoint [2]
0
0
From randomization until end of treatment (up to approximately 2.5 years)
Query!
Secondary outcome [3]
0
0
Duration of Response (DR)
Query!
Assessment method [3]
0
0
DR is defined as the time from the first documentation of objective tumor response (CR or PR) to the first documentation of disease progression or to death due to any cause, whichever occurs first. If tumor progression data included more than 1 date, the first date will be used. DR was calculated as [the date response ended (i.e. date of PD or death) - first CR or PR date + 1)]/30.4. DR would only be calculated for the subgroup of patients with an objective tumor response. Per RECIST v1.1, CR: Complete disappearance of target lesions with exception of nodal disease. All target nodes must decrease to normal size (short axis <10mm). PR: =30% decrease under baseline of the sum of diameters of all target measurable lesions.The short diameter is used in the sum for target nodes, while the longest diameter is used in the sum for all other target lesions. Stable Disease: neither sufficient shrinkage nor increase to qualify for disease progression.
Query!
Timepoint [3]
0
0
From randomization until end of treatment (up to approximately 2.5 years)
Query!
Secondary outcome [4]
0
0
Disease Control (DC)/Clinical Benefit Response (CBR)
Query!
Assessment method [4]
0
0
DC is defined as the overall CR, PR, or stable disease (SD) =24 weeks according to the RECIST version 1.1. Disease Control Rate (DCR) is defined as the patients with CR, PR, or SD =24 weeks relative to all randomized participants. Participants who do not have on-study radiographic tumor reevaluation, who received anti-tumor treatment, a best response of SD=24 weeks, or who died, progressed,or dropped out for any reason prior to achieving reaching a CR or PR and a best response of SD=24 weeks was counted as non-responders in DCR. Per RECIST v1.1, CR: Complete disappearance of target lesions with exception of nodal disease. All target nodes must decrease to normal size (short axis <10mm). PR: =30% decrease under baseline of the sum of diameters of all target measurable lesions. The short diameter is used in the sum for target nodes, while the longest diameter is used in the sum for all other target lesions. SD: neither sufficient shrinkage nor increase to qualify for disease progression
Query!
Timepoint [4]
0
0
From randomization until end of treatment (up to approximately 2.5 years)
Query!
Secondary outcome [5]
0
0
PFS by Tumor Tissue Biomarkers Status, Including Genes (eg, Copy Numbers of CCND1, CDKN2A), Proteins (eg, Ki67, pRb), and RNA Expression (eg, cdk4, cdk6)
Query!
Assessment method [5]
0
0
PFS by biomarker status by Investigator assessment. Progression is defined using RECIST v1.1, as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
Positive is defined as H-Score =1 and negative as H-Score <1. H-Score is calculated as the sum of the % of cells at each level of staining intensity (0, 1+, 2+, and 3+) multiplied by the staining intensity value: H-Score = (% at 0)*0 + (% at 1+)*1 + (% at 2+)*2 + (% at 3+)*3. H-Score values range from 0 to 300.
ER stands for estrogen receptor and Rb stands for retinoblastoma susceptibility gene product.
Query!
Timepoint [5]
0
0
From randomization until end of treatment (up to approximately 24 Months)
Query!
Secondary outcome [6]
0
0
Corrected QT Interval (QTc) Time-matched Change From Baseline on Cycle 1 Day 14
Query!
Assessment method [6]
0
0
Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and sent to a central laboratory for blinded manual adjudication. The average was calculated. The time corresponding to beginning of depolarization to repolarization of the ventricles (QT interval) was adjusted for RR interval using QT and RR from each ECG by Fridericia's formula (QTcF = QT divided by cube root of RR), by Bazette's formula (QTcB = QT divided by square root of RR) and corrected QT interval according to study-specific criteria (QTcS). Time-matched change from baseline values were reported for QTc analysis population.
Query!
Timepoint [6]
0
0
Time-matched triplicate ECGs were collected at 0 (predose), 2, 4, 6 and 8 hours on Day 0 and on Cycle1 Day14
Query!
Secondary outcome [7]
0
0
Percentage of Participants With Corrected QT Interval (QTc)
Query!
Assessment method [7]
0
0
Triplicate 12-lead ECG measurements (each recording separated by approximately 2 minutes) were performed and sent to a central laboratory for blinded manual adjudication. The average was calculated. The time corresponding to beginning of depolarization to repolarization of the ventricles (QT interval) was adjusted for RR interval using QT and RR from each ECG by Fridericia's formula (QTcF = QT divided by cube root of RR), by Bazette's formula (QTcB = QT divided by square root of RR) and corrected QT interval according to study-specific criteria (QTcS). Percentage of participants with post-baseline maximum absolute values and maximum increase from baseline were summarized for the safety analysis population.
Query!
Timepoint [7]
0
0
For safety monitoring triplicate ECGs were obtained at 0 hour (pre-dose) on Day 1 of Cycle 1, Day 14 of Cycles 1 and Cycle 2, then on Day 1 of Cycles 4, 7, and 10. ECGs beyond Cycle 10 were performed as clinically indicated
Query!
Secondary outcome [8]
0
0
Observed Plasma Trough Concentration (Ctrough) at Steady-State
Query!
Assessment method [8]
0
0
Summary of Plasma Palbociclib Within-Patient Mean Steady-State Trough Concentrations.
Query!
Timepoint [8]
0
0
0 hour (predose) on Day 14 of cycles 1 and 2
Query!
Secondary outcome [9]
0
0
Change From Baseline Between Treatment Comparison in Euro Quality of Life (EQ-5D) Index
Query!
Assessment method [9]
0
0
The EuroQol EQ-5D is a 6-item instrument designed to assess health status in terms of a single index value or utility score. It contains 5 descriptors of current health state (mobility, self-care, usual activities, pain or discomfort, and anxiety or depression) with each dimension having 3 levels of function (1=no problem, 2=some problem, and 3=extreme problem). The scores on the 5 descriptors are summarized to create a single summary score. An overall utility score is calculated based on these domains, with a range score from 0 (worse health scenario) to a maximum of 1.0 (best health scenario).
Query!
Timepoint [9]
0
0
From Baseline up to 2.5 years
Query!
Secondary outcome [10]
0
0
Change From Baseline Between Treatment Comparison in Functional Assessment of Cancer Therapy -Breast (FACT-B)
Query!
Assessment method [10]
0
0
FACT is a modular approach to assess participant health-related quality of life using a 'core' set of questions (FACT-G) as well as a cancer site-specific module. The FACT-G is a 27-item compilation of general questions divided into 4 domains: Physical Well-Being, Social/Family Well-Being, Emotional Well-Being, and Functional Well-Being. The FACT-B consisted of the FACT-G (27-item) and a breast-specific module: a 10-item instrument designed to assess participant concerns relating to breast cancer. For all questions, participants were asked to respond to a five-level scale where 0=not at all, 1=a little bit, 2=somewhat, 3=quite a bit, and 4=very much. FACT-B total score = Physical Well-Being + Social/Family Well-Being + Emotional Well-Being + Functional Well-Being + Breast Cancer Subscale. As each of the items ranges from 0-4, the range of possible scores is 0-144, with 0 being the worst possible score and 144 the best.
Query!
Timepoint [10]
0
0
From Baseline up to 2.5 years
Query!
Secondary outcome [11]
0
0
Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs; All Causalities)
Query!
Assessment method [11]
0
0
An AE was any untoward medical occurrence in a clinical investigation participant administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage. SAE was any untoward medical occurrence at any dose that resulted in death; was life-threatening; required hospitalization; resulted in persistent or significant disability or in congenital anomaly/birth defect. TEAE were events that occurred between first dose of study drug and up to 28 days after last dose that were absent before treatment or that worsened relative to pretreatment state. Severity was graded by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 4.0 as Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = life-threatening and Grade 5 = death related to AE.
Query!
Timepoint [11]
0
0
From date of randomization up to 28 days after last dose of study drug, (assessed up to data cut-off date of 15-Nov-2021, approximately 8.7 years)
Query!
Secondary outcome [12]
0
0
Overall Survival (OS)
Query!
Assessment method [12]
0
0
OS was defined as the time from date of randomization to date of death due to any cause. Participants without survival data beyond the date of their last follow-up were censored on the last date they were known to be alive.
Query!
Timepoint [12]
0
0
From date of randomization until death due to any cause or censored, (assessed up to data cut-off date of 15-Nov-2021, approximately 8.7 years)
Query!
Secondary outcome [13]
0
0
Survival Probability at 1 Year, 2 Year and 3 Year
Query!
Assessment method [13]
0
0
One, two or three-year survival probability was defined as the probability of survival 1 year, 2 or 3 years after the date of randomization. The survival probability was estimated using the Kaplan-Meier method and 2-sided 95% confidence interval (CI) was calculated using the product limit method.
Query!
Timepoint [13]
0
0
1, 2 and 3 years after randomization
Query!
Secondary outcome [14]
0
0
Number of Participants With Laboratory Abnormalities by Maximum Common Terminology Criteria for Adverse Events (CTCAE) Grade
Query!
Assessment method [14]
0
0
Laboratory abnormalities included anemia, hemoglobin increased, neutrophils (absolute), platelets, white blood cells, alanine aminotransferase (ALT), alkaline phosphatase, aspartate aminotransferase (AST), bilirubin (total), creatinine, hypercalcemia, hyperkalemia, hypermagnesemia, hypernatremia, hypoalbuminemia, hypocalcemia, hypokalemia, hypomagnesemia and hyponatremia. Laboratory abnormalities were graded by CTCAE version (v) 4.0 as Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe and Grade 4 = life-threatening. Categories with at least 1 non-zero data values are reported.
Query!
Timepoint [14]
0
0
From randomization up to 28 days after last dose of study drug (assessed up to data cut-off date of 15-Nov-2021, approximately 8.7 years)
Query!
Eligibility
Key inclusion criteria
- Adult women with locoregionally recurrent or metastatic disease not amenable to
curative therapy.
- Confirmed diagnosis of ER positive breast cancer
- No prior systemic anti-cancer therapy for advanced ER+ disease.
- Postmenopausal women
- Measurable disease as per Response Evaluation Criterion in Solid Tumors [RECIST] or
bone-only disease
- Eastern Cooperative Oncology Group [ECOG] 0-2
- Adequate organ and marrow function
- Patient must agree to provide tumor tissue
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Confirmed diagnosis of HER2 positive disease
- Patients with advanced, symptomatic, visceral spread that are at risk of life
threatening complication in the short term
- Known uncontrolled or symptomatic CNS metastases
- Prior (neo)adjuvant treatment with letrozole or anastrozole with DFI = 12-months from
completion of treatment.
- Prior treatment with any CDK 4/6 inhibitor.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
22/02/2013
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
9/11/2023
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
666
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,VIC,WA
Query!
Recruitment hospital [1]
0
0
St Vincent's Hospital Sydney - Darlinghurst
Query!
Recruitment hospital [2]
0
0
Laverty Pathology - Port Macquarie
Query!
Recruitment hospital [3]
0
0
Mid North Coast Diagnostic Imaging - Port Macquarie
Query!
Recruitment hospital [4]
0
0
Calvary Mater Newcastle - Waratah
Query!
Recruitment hospital [5]
0
0
Icon Cancer Care - Auchenflower
Query!
Recruitment hospital [6]
0
0
Sunshine Coast University Hospital - Birtinya
Query!
Recruitment hospital [7]
0
0
Icon Cancer Care Corporate Office - South Brisbane
Query!
Recruitment hospital [8]
0
0
Princess Alexandra Hospital - Woolloongabba
Query!
Recruitment hospital [9]
0
0
Royal Adelaide Hospital - Adelaide
Query!
Recruitment hospital [10]
0
0
Bendigo Health Care Group, The Bendigo Hospital Campus - Bendigo
Query!
Recruitment hospital [11]
0
0
Northern Hospital - Epping
Query!
Recruitment hospital [12]
0
0
Royal Melbourne Hospital - Parkville
Query!
Recruitment hospital [13]
0
0
Epworth Healthcare - Richmond
Query!
Recruitment hospital [14]
0
0
Maroondah Hospital - Ringwood East
Query!
Recruitment hospital [15]
0
0
Goulburn Valley Health - Shepparton
Query!
Recruitment hospital [16]
0
0
Fiona Stanley Hospital - Murdoch
Query!
Recruitment postcode(s) [1]
0
0
2010 - Darlinghurst
Query!
Recruitment postcode(s) [2]
0
0
2444 - Port Macquarie
Query!
Recruitment postcode(s) [3]
0
0
2298 - Waratah
Query!
Recruitment postcode(s) [4]
0
0
4066 - Auchenflower
Query!
Recruitment postcode(s) [5]
0
0
4575 - Birtinya
Query!
Recruitment postcode(s) [6]
0
0
4101 - South Brisbane
Query!
Recruitment postcode(s) [7]
0
0
4102 - Woolloongabba
Query!
Recruitment postcode(s) [8]
0
0
5000 - Adelaide
Query!
Recruitment postcode(s) [9]
0
0
3550 - Bendigo
Query!
Recruitment postcode(s) [10]
0
0
3076 - Epping
Query!
Recruitment postcode(s) [11]
0
0
3050 - Parkville
Query!
Recruitment postcode(s) [12]
0
0
3121 - Richmond
Query!
Recruitment postcode(s) [13]
0
0
3135 - Ringwood East
Query!
Recruitment postcode(s) [14]
0
0
3630 - Shepparton
Query!
Recruitment postcode(s) [15]
0
0
6150 - Murdoch
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
California
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Colorado
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Connecticut
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
District of Columbia
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Florida
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Georgia
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Idaho
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Illinois
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Kentucky
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Maryland
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Michigan
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Minnesota
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Mississippi
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Missouri
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Nebraska
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Nevada
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
New York
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Oregon
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
Tennessee
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
Texas
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
Virginia
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
Washington
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
West Virginia
Query!
Country [24]
0
0
United States of America
Query!
State/province [24]
0
0
Wisconsin
Query!
Country [25]
0
0
Belgium
Query!
State/province [25]
0
0
Antwerpen
Query!
Country [26]
0
0
Belgium
Query!
State/province [26]
0
0
Brussels
Query!
Country [27]
0
0
Belgium
Query!
State/province [27]
0
0
Brussel
Query!
Country [28]
0
0
Belgium
Query!
State/province [28]
0
0
Charleroi
Query!
Country [29]
0
0
Belgium
Query!
State/province [29]
0
0
Leuven
Query!
Country [30]
0
0
Belgium
Query!
State/province [30]
0
0
Liege
Query!
Country [31]
0
0
Belgium
Query!
State/province [31]
0
0
Verviers
Query!
Country [32]
0
0
Canada
Query!
State/province [32]
0
0
Alberta
Query!
Country [33]
0
0
Canada
Query!
State/province [33]
0
0
British Columbia
Query!
Country [34]
0
0
Canada
Query!
State/province [34]
0
0
Nova Scotia
Query!
Country [35]
0
0
Canada
Query!
State/province [35]
0
0
Ontario
Query!
Country [36]
0
0
Canada
Query!
State/province [36]
0
0
Quebec
Query!
Country [37]
0
0
Canada
Query!
State/province [37]
0
0
Saskatchewan
Query!
Country [38]
0
0
Czechia
Query!
State/province [38]
0
0
Hradec Kralove
Query!
Country [39]
0
0
France
Query!
State/province [39]
0
0
Anger Cedex 02
Query!
Country [40]
0
0
France
Query!
State/province [40]
0
0
Caen Cedex 5
Query!
Country [41]
0
0
France
Query!
State/province [41]
0
0
Dijon
Query!
Country [42]
0
0
France
Query!
State/province [42]
0
0
La Roche Sur Yon
Query!
Country [43]
0
0
France
Query!
State/province [43]
0
0
Montpellier CEDEX 5
Query!
Country [44]
0
0
France
Query!
State/province [44]
0
0
Nice cedex 2
Query!
Country [45]
0
0
France
Query!
State/province [45]
0
0
Paris Cedex 05
Query!
Country [46]
0
0
France
Query!
State/province [46]
0
0
Rennes
Query!
Country [47]
0
0
France
Query!
State/province [47]
0
0
Saint-Cloud
Query!
Country [48]
0
0
France
Query!
State/province [48]
0
0
St Herblain
Query!
Country [49]
0
0
France
Query!
State/province [49]
0
0
Toulouse CEDEX-9
Query!
Country [50]
0
0
France
Query!
State/province [50]
0
0
Villejuif
Query!
Country [51]
0
0
Germany
Query!
State/province [51]
0
0
Bavaria
Query!
Country [52]
0
0
Germany
Query!
State/province [52]
0
0
Boblingen
Query!
Country [53]
0
0
Germany
Query!
State/province [53]
0
0
Dresden
Query!
Country [54]
0
0
Germany
Query!
State/province [54]
0
0
Erlangen
Query!
Country [55]
0
0
Germany
Query!
State/province [55]
0
0
Hamburg
Query!
Country [56]
0
0
Germany
Query!
State/province [56]
0
0
Kiel
Query!
Country [57]
0
0
Germany
Query!
State/province [57]
0
0
Magdeburg
Query!
Country [58]
0
0
Germany
Query!
State/province [58]
0
0
Mainz
Query!
Country [59]
0
0
Germany
Query!
State/province [59]
0
0
Muenchen
Query!
Country [60]
0
0
Germany
Query!
State/province [60]
0
0
Munich
Query!
Country [61]
0
0
Germany
Query!
State/province [61]
0
0
Trier
Query!
Country [62]
0
0
Hungary
Query!
State/province [62]
0
0
Budapest
Query!
Country [63]
0
0
Hungary
Query!
State/province [63]
0
0
Györ
Query!
Country [64]
0
0
Hungary
Query!
State/province [64]
0
0
Nyiregyhaza
Query!
Country [65]
0
0
Hungary
Query!
State/province [65]
0
0
Szeged
Query!
Country [66]
0
0
Ireland
Query!
State/province [66]
0
0
Cork
Query!
Country [67]
0
0
Ireland
Query!
State/province [67]
0
0
Dublin 4
Query!
Country [68]
0
0
Ireland
Query!
State/province [68]
0
0
Dublin
Query!
Country [69]
0
0
Ireland
Query!
State/province [69]
0
0
Galway
Query!
Country [70]
0
0
Ireland
Query!
State/province [70]
0
0
Limerick
Query!
Country [71]
0
0
Ireland
Query!
State/province [71]
0
0
Waterford
Query!
Country [72]
0
0
Italy
Query!
State/province [72]
0
0
BO
Query!
Country [73]
0
0
Italy
Query!
State/province [73]
0
0
FC
Query!
Country [74]
0
0
Italy
Query!
State/province [74]
0
0
Milan
Query!
Country [75]
0
0
Italy
Query!
State/province [75]
0
0
Avellino
Query!
Country [76]
0
0
Italy
Query!
State/province [76]
0
0
Pisa
Query!
Country [77]
0
0
Italy
Query!
State/province [77]
0
0
Roma
Query!
Country [78]
0
0
Italy
Query!
State/province [78]
0
0
Sora (FR)
Query!
Country [79]
0
0
Japan
Query!
State/province [79]
0
0
Aichi
Query!
Country [80]
0
0
Japan
Query!
State/province [80]
0
0
Chiba
Query!
Country [81]
0
0
Japan
Query!
State/province [81]
0
0
Ehime
Query!
Country [82]
0
0
Japan
Query!
State/province [82]
0
0
Hokkaido
Query!
Country [83]
0
0
Japan
Query!
State/province [83]
0
0
Kumamoto
Query!
Country [84]
0
0
Japan
Query!
State/province [84]
0
0
Saitama
Query!
Country [85]
0
0
Japan
Query!
State/province [85]
0
0
Tokyo
Query!
Country [86]
0
0
Japan
Query!
State/province [86]
0
0
Fukuoka
Query!
Country [87]
0
0
Japan
Query!
State/province [87]
0
0
Hiroshima
Query!
Country [88]
0
0
Japan
Query!
State/province [88]
0
0
Iwate
Query!
Country [89]
0
0
Japan
Query!
State/province [89]
0
0
Kagoshima
Query!
Country [90]
0
0
Japan
Query!
State/province [90]
0
0
Niigata
Query!
Country [91]
0
0
Japan
Query!
State/province [91]
0
0
Osaka
Query!
Country [92]
0
0
Korea, Republic of
Query!
State/province [92]
0
0
Gyeonggi-do
Query!
Country [93]
0
0
Korea, Republic of
Query!
State/province [93]
0
0
Seoul
Query!
Country [94]
0
0
Poland
Query!
State/province [94]
0
0
Mazovia
Query!
Country [95]
0
0
Poland
Query!
State/province [95]
0
0
Gdansk
Query!
Country [96]
0
0
Poland
Query!
State/province [96]
0
0
Zory
Query!
Country [97]
0
0
Russian Federation
Query!
State/province [97]
0
0
Kursk Region
Query!
Country [98]
0
0
Russian Federation
Query!
State/province [98]
0
0
Leningrad Region
Query!
Country [99]
0
0
Russian Federation
Query!
State/province [99]
0
0
Kazan
Query!
Country [100]
0
0
Russian Federation
Query!
State/province [100]
0
0
Moscow Area
Query!
Country [101]
0
0
Russian Federation
Query!
State/province [101]
0
0
Moscow
Query!
Country [102]
0
0
Russian Federation
Query!
State/province [102]
0
0
Omsk
Query!
Country [103]
0
0
Russian Federation
Query!
State/province [103]
0
0
Ryazan
Query!
Country [104]
0
0
Russian Federation
Query!
State/province [104]
0
0
Saint-Petersburg
Query!
Country [105]
0
0
Russian Federation
Query!
State/province [105]
0
0
St Petersburg
Query!
Country [106]
0
0
Russian Federation
Query!
State/province [106]
0
0
Ufa
Query!
Country [107]
0
0
Spain
Query!
State/province [107]
0
0
Barcelona
Query!
Country [108]
0
0
Spain
Query!
State/province [108]
0
0
Islas Baleares
Query!
Country [109]
0
0
Spain
Query!
State/province [109]
0
0
Madrid
Query!
Country [110]
0
0
Spain
Query!
State/province [110]
0
0
Santa CRUZ DE Tenerife
Query!
Country [111]
0
0
Spain
Query!
State/province [111]
0
0
Badajoz
Query!
Country [112]
0
0
Spain
Query!
State/province [112]
0
0
Donostia- San Sebastian
Query!
Country [113]
0
0
Spain
Query!
State/province [113]
0
0
Jaen
Query!
Country [114]
0
0
Spain
Query!
State/province [114]
0
0
L'Hospitalet De Llobregat (Barcelona)
Query!
Country [115]
0
0
Spain
Query!
State/province [115]
0
0
La Coruna
Query!
Country [116]
0
0
Spain
Query!
State/province [116]
0
0
Lleida
Query!
Country [117]
0
0
Spain
Query!
State/province [117]
0
0
Sevilla
Query!
Country [118]
0
0
Spain
Query!
State/province [118]
0
0
Valencia
Query!
Country [119]
0
0
Taiwan
Query!
State/province [119]
0
0
Taipei City
Query!
Country [120]
0
0
Taiwan
Query!
State/province [120]
0
0
Taipei
Query!
Country [121]
0
0
Ukraine
Query!
State/province [121]
0
0
Dnipro
Query!
Country [122]
0
0
Ukraine
Query!
State/province [122]
0
0
Kharkiv
Query!
Country [123]
0
0
Ukraine
Query!
State/province [123]
0
0
Lviv
Query!
Country [124]
0
0
Ukraine
Query!
State/province [124]
0
0
Makiivka
Query!
Country [125]
0
0
Ukraine
Query!
State/province [125]
0
0
Sumy
Query!
Country [126]
0
0
Ukraine
Query!
State/province [126]
0
0
Uzhgorod
Query!
Country [127]
0
0
Ukraine
Query!
State/province [127]
0
0
Zaporizhzhia
Query!
Country [128]
0
0
Ukraine
Query!
State/province [128]
0
0
Zaporizhzhya
Query!
Country [129]
0
0
United Kingdom
Query!
State/province [129]
0
0
Kent
Query!
Country [130]
0
0
United Kingdom
Query!
State/province [130]
0
0
Scotland
Query!
Country [131]
0
0
United Kingdom
Query!
State/province [131]
0
0
London
Query!
Country [132]
0
0
United Kingdom
Query!
State/province [132]
0
0
Manchester
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Pfizer
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The study is designed to compare the clinical benefit following treatment with letrozole in
combination with PD-0332991 versus letrozole in combination with placebo in postmenopausal
women with ER(+)/HER2(-) advanced breast cancer who have not received prior systemic anti
cancer therapies for their advanced/metastatic disease.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT01740427
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Pfizer CT.gov Call Center
Query!
Address
0
0
Pfizer
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT01740427
Download to PDF